Skip to main content
Full access
Letter to the Editor
Published Online: 1 September 2000

Lamotrigine and Clozapine for Bipolar Disorder

Publication: American Journal of Psychiatry
To the Editor:
Treatment-resistant bipolar disorder can be one of the most challenging conditions to manage. There is a need to develop more effective treatment strategies, including complex regimens of combination therapy. Clozapine has been used to treat bipolar disorder that has been nonresponsive to lithium and anticonvulsant therapy, but it appears to be less effective in treating the depressed phase of the illness (1). Lamotrigine has recently been shown to possess efficacy in the treatment of bipolar depression without increasing the rate of switching into mania (2, 3). We report here a case of a patient with bipolar I disorder who was partially responsive to lithium and divalproex whose treatment was augmented with lamotrigine and clozapine.
Mr. A, a 46-year-old man with bipolar I disorder, was referred for follow-up care after hospitalization for 7 months for treatment of mania accompanied by grandiose delusions. During hospitalization he was treated with 300 mg/day of quetiapine, 1200 mg/day of lithium (serum level=1.1 meq/liter), and 2000 mg/day of divalproex (serum level=65 μg/ml). He had previously been unresponsive to adequate trials of carbamazepine, fluoxetine, nortriptyline, amitriptyline, protriptyline, tranylcypromine, bupropion, methylphenidate, l-thyroxine, risperidone, olanzapine, and cognitive behavior psychodynamic psychotherapy. Since life charting suggested that Mr. A was due to cycle into severe depression, lamotrigine therapy was begun and titrated to 150 mg/day over 8 weeks. His depression disappeared after 21 days of treatment.
After a 5-day period of euthymia Mr. A cycled into mania, which led to the initiation of clozapine treatment, starting at 25 mg/day and gradually increasing to 450 mg/day. After augmentation of divalproex and lamotrigine therapy with clozapine, his mood stabilized. Lithium and quetiapine treatment were then gradually discontinued. Previous side effects, which included tremors, weight gain, and listlessness, subsided with the discontinuation of lithium. After 5 months of treatment Mr. A elected to decrease his dose of clozapine to 200 mg/day because of excessive daytime fatigue; he subsequently relapsed into a mild 2-month depression that disappeared after clozapine therapy was resumed. Adjunctive methylphenidate, 20 mg b.i.d., was used to manage his persistent fatigue. Despite the side effects of excessive salivation and daytime fatigue, he has tolerated the combination of divalproex, lamotrigine, and clozapine and remained without symptoms of mania for 7 months, after a 34-year history of periodic mania and a 10-year history of continuous circular cycling.
This case suggests that complex regimens of combination therapy can be safe and effective in the treatment of patients with complex, lifelong histories of treatment-resistant bipolar I disorder. The use of divalproex, lamotrigine, and clozapine in this patient was reasonably well tolerated. Controlled trials are needed to more definitely explore the safety and efficacy of combination therapy in the treatment of bipolar disorder.

References

1.
Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY: Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759–764
2.
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60:79–88
3.
Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE Jr, Rhodes L, Bolden-Watson C, Zhou J, Ascher JA: Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156:1019–1023

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1523
PubMed: 10964878

History

Published online: 1 September 2000
Published in print: September 2000

Authors

Affiliations

JOSEPH R. CALABRESE, M.D.
PRASHANT GAJWANI, M.D.
Cleveland, Ohio

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share